The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Developments in the use of different classes of BTK inhibitors for CLL treatment
In this video, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, University of Leeds, Leeds, UK, gives a detailed summary on recent developments in the use of Bruton’s tyrosine kinase (BTK) inhibitors, focusing on three main classes: the original, ibrutinib, the more selective irreversible inhibitors zanubrutinib and acalabrutinib, and the third generation reversible BTK inhibitor, pirtobrutinib. Dr Hillmen briefly discusses the advantages seen with the use of these inhibitors, such as lower cardiac toxicity, fewer nuisance side effects, and the promising results that have been demonstrated in clinical trials. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
